SLC2A1 and hepatocellular carcinoma: Although Amann et al proposed that combined inhibition of HIF-1α and GLUT-1 may be a novel therapeutic stategy in hepatocellular carcinoma [20], there is no report on the simultaneous inhibition of HIF-1α and GLUT-1 in laryngeal cancer.